A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
Janssen-Cilag Ltd.
200 participants
Feb 9, 2026
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Eligibility
Inclusion Criteria5
- Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
- Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
- Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
- Participants must understand and be willing and able to answer patient-reported outcomes (PROs)
- Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
Exclusion Criteria4
- Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid
- Pregnancy or breastfeeding
- Currently enrolled in an interventional study
- Currently enrolled in an observational study sponsored or managed by a Janssen company
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07449234